Emmanuel Farber, a pathologist who made contributions to the understanding of chemical carcinogenesis, died Sunday, Aug. 3.
Ethicon, the Johnson & Johnson subsidiary that manufactures nearly three-quarters of laparoscopic power morcellators on the market, has requested a withdrawal of the controversial devices.
FDA approved Zydelig (idelalisib) tablets for the treatment of three B-cell blood cancers.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase II study by the University of Florida Proton Therapy Institute shows that the use of proton therapy following chemotherapy in 15 patients with Hodgkin lymphoma has a success rate similar to the conventional treatments with a reduction of radiation outside of the target area, potentially reducing the risk of late effects caused by radiation.
An NCI study found that a negative HPV screening test result is a better predictor of low cervical cancer risk than a negative Pap test.
A phase II study of older patients with untreated acute myeloid leukemia showed that treatment with volasertib and low-dose cytarabine more than doubled the objective response rate compared to cytarabine chemotherapy alone.
Somatuline increased progression-free survival over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors in a randomized phase III trial.
An independent data monitoring committee recommended an early stop a phase III trial of Mekinist and Tafinlar in patients with BRAF V600E or V600K mutation-positive unresectable or metastatic cutaneous melanoma, following a demonstrated overall survival benefit.
A phase III trial of trifluridine and tipiracil hydrochloride significantly improved both overall and progression-free survival in refractory metastatic colorectal cancer that had progressed after standard therapies.